Argentina’s Ministry of Health has implemented stricter rules for its medical cannabis program, REPROCANN, aiming to improve oversight and ensure professional competency. These changes affect solidarity cultivators, NGOs, and physicians, potentially impacting patient access to cannabis treatments.
Avicanna Inc., a leading manufacturer of cannabinoid-based products, announced impressive second-quarter financial results, highlighting revenue growth of 85% year-over-year and significant progress in clinical trials. The company’s focus on real-world evidence studies and expansion into new markets positions them for continued growth in the medical cannabis space.
Germany’s cannabis market is rapidly expanding, with Tilray, Aurora, and Demecan emerging as key players in domestic cultivation. These companies are strategically positioned to capitalize on the growing medical cannabis market, projected to reach €1.7 billion by 2025. This article delves into the operations and contributions of each company, highlighting their role in shaping Germany’s cannabis landscape.
In a historic shift in American drug policy, the U.S. Drug Enforcement Administration (DEA) plans to reclassify marijuana as a less dangerous drug. This move, announced during an election year, comes as the Biden administration continues to prioritize marijuana sentencing reforms. The DEA’s proposal, if passed, would acknowledge the medical uses of cannabis and its lower potential for abuse compared to some other drugs. However, it would not legalize recreational marijuana use.
